CX Institutional Purchases 14,809 Shares of Harmony Biosciences Holdings, Inc. $HRMY

CX Institutional grew its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 6.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 259,496 shares of the company’s stock after acquiring an additional 14,809 shares during the period. CX Institutional owned about 0.45% of Harmony Biosciences worth $9,448,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Pacer Advisors Inc. lifted its stake in shares of Harmony Biosciences by 9.7% in the 1st quarter. Pacer Advisors Inc. now owns 318,527 shares of the company’s stock valued at $8,922,000 after purchasing an additional 28,174 shares during the period. Segall Bryant & Hamill LLC grew its stake in Harmony Biosciences by 65.0% in the first quarter. Segall Bryant & Hamill LLC now owns 30,059 shares of the company’s stock worth $842,000 after purchasing an additional 11,841 shares during the period. Edgestream Partners L.P. grew its stake in Harmony Biosciences by 52.1% in the first quarter. Edgestream Partners L.P. now owns 138,130 shares of the company’s stock worth $3,869,000 after purchasing an additional 47,303 shares during the period. Amundi raised its holdings in Harmony Biosciences by 93.0% in the first quarter. Amundi now owns 12,308 shares of the company’s stock worth $345,000 after purchasing an additional 5,931 shares in the last quarter. Finally, California State Teachers Retirement System raised its holdings in Harmony Biosciences by 40.9% in the first quarter. California State Teachers Retirement System now owns 57,928 shares of the company’s stock worth $1,623,000 after purchasing an additional 16,821 shares in the last quarter. Institutional investors own 86.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HRMY. Deutsche Bank Aktiengesellschaft raised their price objective on Harmony Biosciences from $30.00 to $36.00 and gave the company a “hold” rating in a research report on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of Harmony Biosciences in a research report on Thursday, July 16th. Truist Financial increased their price target on shares of Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a research note on Friday, May 8th. Mizuho lifted their price target on shares of Harmony Biosciences from $50.00 to $51.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Weiss Ratings raised shares of Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Harmony Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.62.

Harmony Biosciences Trading Up 1.0%

Harmony Biosciences stock opened at $35.60 on Tuesday. Harmony Biosciences Holdings, Inc. has a 12 month low of $25.52 and a 12 month high of $40.87. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of 14.35, a price-to-earnings-growth ratio of 0.33 and a beta of 0.96. The business’s fifty day simple moving average is $34.59 and its two-hundred day simple moving average is $32.52. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.21). The company had revenue of $215.39 million for the quarter, compared to the consensus estimate of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. Harmony Biosciences’s revenue was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.78 earnings per share. As a group, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 3.3 earnings per share for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.